Halozyme Therapeutics, Inc. Reports First Quarter 2013 Financial Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN DIEGO, May 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2013.
"With the potential for 3 new product launches over the next 12 months and continued progress on the Hylenex® brand, I am pleased with the steps we are making towards our near term revenue drivers," said Gregory I. Frost , Ph.D., President and Chief Executive Officer, Halozyme.
Help employers find you! Check out all the jobs and post your resume.
SAN DIEGO, May 8, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the quarter ended March 31, 2013.
"With the potential for 3 new product launches over the next 12 months and continued progress on the Hylenex® brand, I am pleased with the steps we are making towards our near term revenue drivers," said Gregory I. Frost , Ph.D., President and Chief Executive Officer, Halozyme.
Help employers find you! Check out all the jobs and post your resume.